General Information of Drug (ID: DMIF9DZ)

Drug Name
BGB-3113 Drug Info
Indication
Disease Entry ICD 11 Status REF
B-cell lymphoma 2A86 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMIF9DZ

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tyrosine-protein kinase BTK (ATK) TTGM6VW BTK_HUMAN Inhibitor [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Tyrosine-protein kinase BTK (ATK) DTT BTK 3.838 3.897 5.053 5.897
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease B-cell lymphoma
ICD Disease Classification 2A86
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tyrosine-protein kinase BTK (ATK) DTT BTK 3.54E-01 0.24 0.56
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)